Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2017
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 24 May 2017 Planned End Date changed from 21 Aug 2017 to 31 Dec 2017.
- 27 Dec 2016 Status changed from not yet recruiting to recruiting.
- 09 Sep 2016 New trial record